Innovative therapy for critical limb ischemia

AnGes MG is poised to create a new drug market with Collategene. To download the full article, please sign in.

Page of
Go to the profile of AnGes MG

AnGes MG

AnGes is a clinical-stage biopharmaceutical company based in Japan. The company is focused on the development and commercialisation of gene-based medicines including gene therapy, oligonucleotides and DNA vaccines. Its lead product candidate is Collategene (HGF plasmid) for critical limb ischemia, for which a global phase III study is ongoing. The company is conducting another phase III trial for NF-kB Decoy Oligo for atopic dermatitis in Japan. There are several early-stage programmes including NF-kB Decoy Oligo for low back pain and DNA vaccine for hypertension. In addition, the company has been marketing Naglazyme, enzyme replacement therapy for MPS (Mucopolysaccharidosis) VI, since 2008 in Japan that was in-licensed from BioMarin Pharmaceutical. The company seeks pharma partners for the commercialisation of the products under development, particularly for the territory outside of Japan, whereas looks for an in-licensing opportunity of products for Japan in orphan indications. AnGes is a publicly-traded company on the Tokyo Stock Exchange and has its headquarters in Tokyo, laboratory in Osaka (registered head office) and overseas subsidiaries in Maryland, USA and in the UK each.

Comments are disabled